Cancer Anorexia-Cachexia Syndrome – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Cancer Anorexia-Cachexia Syndrome – Drugs In Development, 2024 report and make more profitable business decisions.
Cancer anorexia-cachexia syndrome is defined as progressive weight loss associated with malignancy and is characterized by loss of appetite (anorexia), skeletal muscle wasting, and reduced adipose tissue. Approximately 50% of cancer patients report abnormalities of eating behavior at the time of first diagnosis and prevalence is even higher at approximately 65%. The incidence of weight loss upon diagnosis varies greatly according to the tumor site.
The Cancer Anorexia-Cachexia Syndrome drugs in development market research report provide comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cancer Anorexia-Cachexia Syndrome and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Cancer Anorexia-Cachexia Syndrome | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 33 molecules, with 32 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Cancer Anorexia-Cachexia Syndrome therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Cancer Anorexia-Cachexia Syndrome pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Cancer Anorexia-Cachexia Syndrome treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AAVogen IncActimed Therapeutics Ltd
Aeterna Zentaris Inc
Animuscure Co Ltd
Aphios Corp
Artelo Biosciences Inc
ARTHEx Biotech SL
AtoGen Co Ltd
AVEO Pharmaceuticals Inc
Betula Pharma
Byomass Inc
Caelus Health
CNBX Pharmaceuticals Inc
Endevica Bio Inc
Extend Biosciences Inc
FibroGenesis LLC
Helsinn Healthcare SA
Immuneering Corp
Incyte Corp
Kexing Biopharm Co Ltd
Korea Pharma Co Ltd
Kyungpook National University
Larix Bioscience LLC
Mirscience Therapeutics
NGM Biopharmaceuticals Inc
Panorama Research Institute
Pfizer Inc
RaQualia Pharma Inc
Shanghai Jinmante Biological Technology Co Ltd
Specialised Therapeutics Australia Pty Ltd
TMS Co Ltd
University of Turin
VistaGen Therapeutics Inc
Zeria Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Cancer Anorexia-Cachexia Syndrome reports